Fluorescein-based sensors to purify human a-cells for functional and transcriptomic analyses

Abstract

Pancreatic a-cells secrete glucagon, an insulin counter-regulatory peptide hormone critical for the maintenance of glucose homeostasis. Investigation of the function of human a-cells remains a challenge due to the lack of cost-effective purification methods to isolate high-quality a-cells from islets. Here, we use the reaction-based probe diacetylated Zinpyr1 (DA-ZP1) to introduce a novel and simple method for enriching live a-cells from dissociated human islet cells with ~ 95% purity. The a-cells, confirmed by sorting and immunostaining for glucagon, were cultured up to 10 days to form a-pseudoislets. The a-pseudoislets could be maintained in culture without significant loss of viability, and responded to glucose challenge by secreting appropriate levels of glucagon. RNA-sequencing analyses (RNA-seq) revealed that expression levels of key a-cell identity genes were sustained in culture while some of the genes such as DLK1, GSN, SMIM24 were altered in a-pseudoislets in a time-dependent manner. In conclusion, we report a method to sort human primary a-cells with high purity that can be used for downstream analyses such as functional and transcriptional studies.

Data availability

RNA-seq data have been deposited under accession code GSE199412. Further information and requests for resources and reagents should be directed to the corresponding author.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Sevim Kahraman

    Islet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, United States
    Competing interests
    Sevim Kahraman, S.K. is an employee of Boehringer Ingelheim Pharmaceuticals, Inc..
  2. Kimitaka Shibue

    Islet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, United States
    Competing interests
    No competing interests declared.
  3. Dario F De Jesus

    Islet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, United States
    Competing interests
    No competing interests declared.
  4. Hyunki Kim

    Islet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, United States
    Competing interests
    No competing interests declared.
  5. Jiang Hu

    Islet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, United States
    Competing interests
    No competing interests declared.
  6. Debasish Manna

    Chemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, United States
    Competing interests
    No competing interests declared.
  7. Bridget K Wagner

    Chemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, United States
    Competing interests
    No competing interests declared.
  8. Amit Choudhary

    Chemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, United States
    Competing interests
    No competing interests declared.
  9. Rohit N Kulkarni

    Islet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, United States
    For correspondence
    rohit.kulkarni@joslin.harvard.edu
    Competing interests
    Rohit N Kulkarni, is on the Scientific Advisory Board of Novo Nordisk, Biomea and Inversago Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5029-6119

Funding

National Institutes of Health (U01 DK123717)

  • Bridget K Wagner
  • Rohit N Kulkarni

National Institutes of Health (UC4 DK116255)

  • Bridget K Wagner
  • Amit Choudhary
  • Rohit N Kulkarni

National Institutes of Health (R01 067536)

  • Rohit N Kulkarni

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2023, Kahraman et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,368
    views
  • 267
    downloads
  • 0
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Sevim Kahraman
  2. Kimitaka Shibue
  3. Dario F De Jesus
  4. Hyunki Kim
  5. Jiang Hu
  6. Debasish Manna
  7. Bridget K Wagner
  8. Amit Choudhary
  9. Rohit N Kulkarni
(2023)
Fluorescein-based sensors to purify human a-cells for functional and transcriptomic analyses
eLife 12:e85056.
https://doi.org/10.7554/eLife.85056

Share this article

https://doi.org/10.7554/eLife.85056

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Angel D'Oliviera, Xuhang Dai ... Jeffrey S Mugridge
    Research Article

    The SARS-CoV-2 main protease (Mpro or Nsp5) is critical for production of viral proteins during infection and, like many viral proteases, also targets host proteins to subvert their cellular functions. Here, we show that the human tRNA methyltransferase TRMT1 is recognized and cleaved by SARS-CoV-2 Mpro. TRMT1 installs the N2,N2-dimethylguanosine (m2,2G) modification on mammalian tRNAs, which promotes cellular protein synthesis and redox homeostasis. We find that Mpro can cleave endogenous TRMT1 in human cell lysate, resulting in removal of the TRMT1 zinc finger domain. Evolutionary analysis shows the TRMT1 cleavage site is highly conserved in mammals, except in Muroidea, where TRMT1 is likely resistant to cleavage. TRMT1 proteolysis results in reduced tRNA binding and elimination of tRNA methyltransferase activity. We also determined the structure of an Mpro-TRMT1 peptide complex that shows how TRMT1 engages the Mpro active site in an uncommon substrate binding conformation. Finally, enzymology and molecular dynamics simulations indicate that kinetic discrimination occurs during a later step of Mpro-mediated proteolysis following substrate binding. Together, these data provide new insights into substrate recognition by SARS-CoV-2 Mpro that could help guide future antiviral therapeutic development and show how proteolysis of TRMT1 during SARS-CoV-2 infection impairs both TRMT1 tRNA binding and tRNA modification activity to disrupt host translation and potentially impact COVID-19 pathogenesis or phenotypes.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Qian Wang, Jinxin Liu ... Qian Liu
    Research Article

    Paramyxovirus membrane fusion requires an attachment protein for receptor binding and a fusion protein for membrane fusion triggering. Nipah virus (NiV) attachment protein (G) binds to ephrinB2 or -B3 receptors, and fusion protein (F) mediates membrane fusion. NiV-F is a class I fusion protein and is activated by endosomal cleavage. The crystal structure of a soluble GCN4-decorated NiV-F shows a hexamer-of-trimer assembly. Here, we used single-molecule localization microscopy to quantify the NiV-F distribution and organization on cell and virus-like particle membranes at a nanometer precision. We found that NiV-F on biological membranes forms distinctive clusters that are independent of endosomal cleavage or expression levels. The sequestration of NiV-F into dense clusters favors membrane fusion triggering. The nano-distribution and organization of NiV-F are susceptible to mutations at the hexamer-of-trimer interface, and the putative oligomerization motif on the transmembrane domain. We also show that NiV-F nanoclusters are maintained by NiV-F–AP-2 interactions and the clathrin coat assembly. We propose that the organization of NiV-F into nanoclusters facilitates membrane fusion triggering by a mixed population of NiV-F molecules with varied degrees of cleavage and opportunities for interacting with the NiV-G/receptor complex. These observations provide insights into the in situ organization and activation mechanisms of the NiV fusion machinery.